Adding Gazyva (obinutuzumab) to standard-of-care treatment more than doubles the proportion of complete kidney responses in people with proliferative lupus nephritis, a Phase 2 study shows. A Phase 3 study of Gazyva in lupus nephritis is expected to start next year. The findings were presented at two meetings…
News
The Lupus Foundation of America (LFA) is partnering with health informatics company Prometheus Research to develop a next-generation data platform, set to launch next year, to help advance lupus research. LFA will use the platform to expand its Research.forME Lupus Registry, which was launched in 2017…
Adding anifrolumab to standard-of-care treatment significantly reduced disease activity, corticosteroid use, and severity of skin lesions in people with moderate-to-severe systemic lupus erythematosus (SLE), according to data from a Phase 3 trial. The research, “Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus…
Levels of proteins associated with changes in the inner wall of blood vessels — the endothelium —  are higher in children and adolescents with systemic lupus erythematosus (SLE) and are potential biomarkers of disease activity, as well as of brain and kidney involvement, a study suggests. The study, “…
Higher expression of nine genes may help identify people with systemic lupus erythematosus (SLE) who will respond to treatment with Stelara (ustekinumab) — an approved therapy in inflammatory disorders but not in SLE. At the 2019 American College of Rheumatology (ACR)/Association for Rheumatology Health Professionals (ARHP) Annual Meeting,…
A new public-private initiative brings academic and industry researchers from 15 European countries together in a large-scale effort to understand differences and commonalities in seven immune-mediated and inflammatory diseases, including systemic lupus erythematosus (SLE), to better predict a patient’s response to treatment and likely disease progression. The project, called 3TR (for…
People with systemic lupus erythematosus (SLE) who stop treatment with hydroxychloroquine less than 12 months after its start are at a higher risk of flares than those who continue using it for at least one year, a study suggests. The research, “Outcomes of Systemic Lupus Erythematosus in…
The European Commission has approved the use of intravenous Benlysta (belimumab) as an add-on to standard therapy for children ages 5 and older with systemic lupus erythematosus (SLE) and high disease activity. “This approval means that for the first time in Europe these children can be treated with a biologic…
More than 40% of systemic lupus erythematosus (SLE) patients do not comply with hydroxychloroquine (HCQ) therapy, even among people who have insurance coverage, low copayments, and availability of high levels of care, a study reveals. Meanwhile, being older, white, and having more frequent rheumatology visits — suggesting higher…
A Phase 3 trial assessing the potential of voclosporin as an add-on to standard treatment for people with lupus nephritis has completed patient visits. “With the completion of patient visits in the AURORA study, we now look forward to reporting out the efficacy and safety results by the…
Recent Posts
- Twin Phase 3 studies recruiting adults with lupus skin problems in US, Canada
- Understanding how menopause can affect our lupus symptoms
- Discovering a role the vagus nerve plays in chronic pain management
- Recognizing patterns is one of my greatest weapons against lupus flares
- Flaws on the X chromosome may directly trigger lupus in women